| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | November 22, 2024 4:30 P.M. |
| Form: | S-3 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | November 22, 2024 4:30 P.M. |
| Form: | S-3 | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2024 | $10.00 | Outperform | Leerink Partners |
4 - Climb Bio, Inc. (0001768446) (Issuer)
4 - Climb Bio, Inc. (0001768446) (Issuer)
3 - Climb Bio, Inc. (0001768446) (Issuer)
EFFECT - Climb Bio, Inc. (0001768446) (Filer)
S-3 - Climb Bio, Inc. (0001768446) (Filer)
8-K - Climb Bio, Inc. (0001768446) (Filer)
WELLESLEY HILLS, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- December 19, 2024 – Climb Bio, Inc. (NASDAQ:CLYM) today announced that the company will be added to the NASDAQ Biotech Index (NASDAQ:NBI) as part of the annual reconstitution of the 2024 Nasdaq indexes. Climb Bio's inclusion in the Nasdaq Biotechnology Index will be effective prior to market open on Monday, December 23, 2024. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is calculated under a mo
Appointed Douglas Williams, Ph.D. as Chair of the Board of Directors FDA Clearance of Investigational New Drug Application (IND) for systemic lupus erythematosus (SLE) Expanded Management Team with the Appointment of Gary Hao, Ph.D. as Vice President of Chemistry, Manufacturing and Controls Highlights Timing of Key Upcoming Milestones Cash Runway Remains through 2027 Expected to Enable Delivery of Key Value Inflection Points WELLESLEY HILLS, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the quarter
WELLESLEY, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointment of Douglas E. Williams, Ph.D., as Climb Bio's Chair of its Board of Directors. Dr. Williams will assume the role of Chair of the Board, succeeding Andrew Levin, who will remain on the Board as a director, while Liam Ratcliffe will step down from his position as a director. Dr. Williams has over 30 years of executive leadership experience in the biotechnology sector. Throughout his career, Dr. Williams has held leadership roles in research and development, contributing significantly to the creation of drugs such as Leukine®, Enbrel®, Adcetris®, Tecfidera®, Alprolix®, Eloctate® a
SC 13G/A - Climb Bio, Inc. (0001768446) (Subject)
Leerink Partners initiated coverage of Climb Bio with a rating of Outperform and set a new price target of $10.00
WELLESLEY, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointment of Douglas E. Williams, Ph.D., as Climb Bio's Chair of its Board of Directors. Dr. Williams will assume the role of Chair of the Board, succeeding Andrew Levin, who will remain on the Board as a director, while Liam Ratcliffe will step down from his position as a director. Dr. Williams has over 30 years of executive leadership experience in the biotechnology sector. Throughout his career, Dr. Williams has held leadership roles in research and development, contributing significantly to the creation of drugs such as Leukine®, Enbrel®, Adcetris®, Tecfidera®, Alprolix®, Eloctate® a